Globus Medical Inc (NYSE: GMED) has a higher price-to-earnings ratio of 140.47x compared to its average ratio. GMED has 36-month beta value of 1.19. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for GMED is 112.93M, and currently, short sellers hold a 2.21% ratio of that float. The average trading volume of GMED on January 31, 2025 was 1.08M shares.
GMED) stock’s latest price update
Globus Medical Inc (NYSE: GMED) has experienced a rise in its stock price by 0.36 compared to its previous closing price of 92.79. However, the company has seen a gain of 0.76% in its stock price over the last five trading days. globenewswire.com reported 2025-01-30 that AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2024 after the market close on Thursday, February 20, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
GMED’s Market Performance
Globus Medical Inc (GMED) has seen a 0.76% rise in stock performance for the week, with a 11.44% gain in the past month and a 25.50% surge in the past quarter. The volatility ratio for the week is 1.98%, and the volatility levels for the past 30 days are at 2.16% for GMED. The simple moving average for the last 20 days is 4.78% for GMED’s stock, with a simple moving average of 28.44% for the last 200 days.
Analysts’ Opinion of GMED
Many brokerage firms have already submitted their reports for GMED stocks, with BofA Securities repeating the rating for GMED by listing it as a “Neutral.” The predicted price for GMED in the upcoming period, according to BofA Securities is $97 based on the research report published on January 10, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see GMED reach a price target of $100, previously predicting the price at $83. The rating they have provided for GMED stocks is “Overweight” according to the report published on December 02nd, 2024.
Wells Fargo gave a rating of “Overweight” to GMED, setting the target price at $78 in the report published on August 07th of the previous year.
GMED Trading at 8.81% from the 50-Day Moving Average
After a stumble in the market that brought GMED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.80% of loss for the given period.
Volatility was left at 2.16%, however, over the last 30 days, the volatility rate increased by 1.98%, as shares surge +12.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.82% upper at present.
During the last 5 trading sessions, GMED rose by +0.76%, which changed the moving average for the period of 200-days by +80.22% in comparison to the 20-day moving average, which settled at $88.87. In addition, Globus Medical Inc saw 12.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GMED starting from Pfeil Keith W, who sale 14,167 shares at the price of $88.29 back on Jan 10 ’25. After this action, Pfeil Keith W now owns 0 shares of Globus Medical Inc, valued at $1,250,770 using the latest closing price.
Pfeil Keith W, the Officer of Globus Medical Inc, proposed sale 14,167 shares at $88.29 during a trade that took place back on Jan 10 ’25, which means that Pfeil Keith W is holding shares at $1,250,772 based on the most recent closing price.
Stock Fundamentals for GMED
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.55 for the gross margin
The net margin for Globus Medical Inc stands at 0.04. The total capital return value is set at 0.04. Equity return is now at value 2.22, with 1.75 for asset returns.
Based on Globus Medical Inc (GMED), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at 0.78. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is 21.68.
Currently, EBITDA for the company is 346.58 million with net debt to EBITDA at -0.17. When we switch over and look at the enterprise to sales, we see a ratio of 5.08. The receivables turnover for the company is 4.21for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.51.
Conclusion
To put it simply, Globus Medical Inc (GMED) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
